Molecular mechanisms of chemoresistance in osteosarcoma (review)

Oncology Letters

Volumn 7, Issue 5, 2014, Pages 1352-1362

  He, Hongtao ^a   Ni, Jiangdong ^a   Huang, Jun ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Chemoresistance; Osteosarcoma

Indexed keywords

APURINIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUTATHIONE TRANSFERASE P1; HIGH MOBILITY GROUP B1 PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MULTIDRUG RESISTANCE PROTEIN; REDUCED FOLATE CARRIER; SOMATOMEDIN C RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; VASCULOTROPIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

APOPTOSIS; AUTOPHAGY; AUTOPSY; CANCER STEM CELL; CELL CYCLE; CLINICAL TRIAL (TOPIC); DRUG ACCUMULATION; DRUG INACTIVATION; DRUG MECHANISM; EXCISION REPAIR; GENE EXPRESSION; HUMAN; OSTEOSARCOMA; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE;

EID: 84896259603     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.1935     Document Type: Review

References (156)

1. Chou AJ and Gorlick R: Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer There 6: 1075-1085, 2006.
2. Longhi A, Errani C, De Paolis M, Mercuri M and Bacci G: Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 32: 423-436, 2006.
3. Chou AJ, Geller DS and Gorlick R: Therapy for osteosarcoma: where do we go from here? Paediatr Drugs 10: 315-327, 2008.
4. Eilber FR and Rosen G: Adjuvant chemotherapy for osteosarcoma. Semin Oncol 16: 312-322, 1989.
5. Sakamoto A and Iwamoto Y: Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy: Rev Recent Clin Trials 3: 228-231, 2008.
6. Bertino JR: Karnofsky memorial lecture. Ode to methotrexate. J Clin Oncol 11: 5-14, 1993.
7. Hattinger CM, Reverter-Branchat G, Remondini D, et al: Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques. Eur J Cell Biol 82: 483-493, 2003.
8. Guo W, Healey JH, Meyers PA, Ladanyi M, Huvos AG, Bertino JR and Gorlick R: Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res 5: 621-627, 1999.
9. Patiño-García A, Zalacaín M, Marrodán L, San-Julián M and Sierrasesúmaga L: Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression. J Pediatr 154: 688-693, 2009.
10. Ifergan I, Meller I, Issakov J and Assaraf YG: Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensitivity. Cancer 98: 1958-1966, 2003.
11. Flintoff WF, Sadlish H, Gorlick R, Yang R and Williams FM: Functional analysis of altered reduced folate carrier sequence changes identified in osteosarcomas. Biochim Biophys Acta 1690: 110-117, 2004.
12. Serra M, Reverter-Branchat G, Maurici D, et al: Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells. Ann Oncol 15: 151-160, 2004.
13. Yang R, Sowers R, Mazza BA, et al: Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples. Clin Cancer Res 9: 837-844, 2003.
14. Trippett T, Meyers P, Gorlick R, et al: High dose trimetrexate with leucovorin protection in recurrent childhood malignancies: a phase II trial. J Clin Oncol (ASCO Annual Meeting Abstracts): 9: 889, 1999.
15. Weinstein RS, Kuszak JR, Kluskens LF and Coon JS: P-glycoproteins in pathology: the multidrug resistance gene family in humans. Hum Pathol 21: 34-48, 1990.
16. Safa AR, Stern RK, Choi K, et al: Molecular basis of preferential resistance to colchicine in multidrug-resistant human cells conferred by Gly-185Val-185 substitution in P-glycoprotein. Proc Natl Acad Sci USA 87: 7225-7229, 1990.
17. Bramwell VH: Osteosarcomas and other cancers of bone. Curr Opin Oncol 12: 330-336, 2000.
18. Park YB, Kim HS, Oh JH and Lee SH: The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma. Int Orthop 24: 307-310, 2001.
19. Gomes CM, van Paassen H, Romeo S, et al: Multidrug resistance mediated by ABC transporters in osteosarcoma cell lines: mRNA analysis and functional radiotracer studies. Nucl Med Biol 33: 831-840, 2006.
20. Serra M, Pasello M, Manara MC, et al: May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol. Int J Oncol 29: 1459-1468, 2006.
21. Baldini N, Scotlandi K, Serra M, Picci P, Bacci G, Sottili S and Campanacci M: P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy. J Orthop Res 17: 629-632, 1999.
22. Kusuzaki K, Hirata M, Takeshita H, Murata H, Hashiguchi S, Ashihara T and Hirasawa Y: Relationship between P-glycoprotein positivity, doxorubicin binding ability and histologic response to chemotherapy in osteosarcomas. Cancer Lett 138: 203-208, 1999.
23. Trammell RA, Johnson CB, Barker JR, Bell RS and Allan DG: Multidrug resistance-1 gene expression does not increase during tumor progression in the MGH-OGS murine osteosarcoma tumor model. J Orthop Res 18: 449-455, 2000.
24. Wunder JS, Bull SB, Aneliunas V, et al: MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol 18: 2685-2694, 2000.
25. Pakos EE and Ioannidis JP: The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis. Cancer 98: 581-589, 2003.
26. Sorensen FB, Jensen K, Vaeth M, et al: Immunohistochemical estimates of angiogenesis, proliferative activity, p53 expression, and multiple drug resistance have no prognostic impact in osteosarcoma: A comparative clinicopathological investigation. Sarcoma 2008: 874075, 2008.
27. Takeshita H, Kusuzaki K, Murata H, et al: Osteoblastic differentiation and P-glycoprotein multidrug resistance in a murine osteosarcoma model. Br J Cancer 82: 1327-1331, 2000.
28. Susa M, Iyer AK, Ryu K, Choy E, Hornicek FJ, Mankin H, Milane L, Amiji MM and Duan Z: Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. PLoS One 5: e10764, 2010.
29. Susa M, Iyer AK, Ryu K, Hornicek FJ, Mankin H, Amiji MM and Duan Z: Doxorubicin loaded polymeric nanoparticulate delivery system to overcome drug resistance in osteosarcoma. BMC Cancer 9: 399, 2009.
30. Kobayashi E, Iyer AK, Hornicek FJ, Amiji MM and Duan Z: Lipid-functionalized dextran nanosystems to overcome multidrug resistance in cancer: a pilot study. Clin Orthop Relat Res 471: 915-925, 2013.
31. Townsend DM and Tew KD: The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22: 7369-7375, 2003.
32. Tew KD: Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 54: 4313-4320, 1994.
33. Shoieb A and Hahn K: Detection and significance of glutathione-S-transferase pi in osteogenic tumors of dogs. Int J Oncol 10: 635-639, 1997.
34. Uozaki H, Horiuchi H, Ishida T, Iijima T, Imamura T and Machinami R: Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase pi, heat shock protein 27, and lung resistance-related protein) in osteosarcoma. Relationship with poor prognosis. Cancer 79: 2336-2344, 1997.
35. Wei L, Song XR, Wang XW, Li M and Zuo WS: Expression of MDR1 and GST-pi in osteosarcoma and soft tissue sarcoma and their correlation with chemotherapy resistance. Zhonghua Zhong Liu Za Zhi 28: 445-448, 2006 (In Chinese).
36. Bruheim S, Bruland OS, Breistol K, Maelandsmo GM and Fodstad O: Human osteosarcoma xenografts and their sensitivity to chemotherapy. Pathol Oncol Res 10: 133-141, 2004.
37. Huang G, Mills L and Worth LL: Expression of human glutathione S-transferase P1 mediates the chemosensitivity of osteosarcoma cells. Mol Cancer Ther 6: 1610-1619, 2007.
38. Windsor RE, Strauss SJ, Kallis C, Wood NE and Whelan JS: Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study. Cancer 118: 1856-1867, 2012.
39. Zhang SL, Mao NF, Sun JY, Shi ZC, Wang B and Sun YJ: Predictive potential of glutathione S-transferase polymorphisms for prognosis of osteosarcoma patients on chemotherapy. Asian Pac J Cancer Prev 13: 2705-2709, 2012.
40. Yang LM, Li XH and Bao CF: Glutathione S-transferase P1 and DNA polymorphisms influence response to chemotherapy and prognosis of bone tumors. Asian Pac J Cancer Prev 13: 5883-5886, 2012.
41. Pasello M, Michelacci F, Scionti I, Hattinger CM, Zuntini M, Caccuri AM, Scotlandi K, Picci P and Serra M: Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma. Cancer Res 68: 6661-6668, 2008.
42. Pasello M, Manara MC, Michelacci F, et al: Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy. Anal Cell Pathol (Amst) 34: 131-145, 2011.
43. Sau A, Filomeni G, Pezzola S, et al: Targeting GSTP1-1 induces JNK activation and leads to apoptosis in cisplatin-sensitive and -resistant human osteosarcoma cell lines. Mol Biosyst 8: 994-1006, 2012.
44. Sak SC, Harnden P, Johnston CF, Paul AB and Kiltie AE: APE1 and XRCC1 protein expression levels predict cancer-specific survival following radical radiotherapy in bladder cancer. Clin Cancer Res 11: 6205-6211, 2005.
45. Evans AR, Limp-Foster M and Kelley MR: Going APE over ref-1. Mutat Res 461: 83-108, 2000.
46. Silber JR, Bobola MS, Blank A, Schoeler KD, Haroldson PD, Huynh MB and Kolstoe DD: The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress. Clin Cancer Res 8: 3008-3018, 2002.
47. Yang S, Irani K, Heffron SE, Jurnak F and Meyskens FL Jr: Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (Ape/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an Ape1/Ref-1 inhibitor. Mol Cancer Ther 4: 1923-1935, 2005.
48. Wang D, Luo M and Kelley MR: Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Mol Cancer Ther 3: 679-686, 2004.
49. Wang D, Zhong ZY, Li MX, Xiang DB and Li ZP: Vector-based Ape1 small interfering RNA enhances the sensitivity of human osteosarcoma cells to endostatin in vivo. Cancer Sci 98: 1993-2001, 2007.
50. Yang JL, Yang D, Cogdell D, et al: APEX1 gene amplification and its protein overexpression in osteosarcoma: correlation with recurrence, metastasis, and survival. Technol Cancer Res Treat 9: 161-169, 2010.
51. Luo M and Kelley MR: Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone. Anticancer Res 24: 2127-2134, 2004.
52. Madhusudan S, Smart F, Shrimpton P, et al: Isolation of a small molecule inhibitor of base excision repair. Nucleic Acids Res 33: 4711-4724, 2005.
53. Seiple LA, Cardellina JH II, Akee R and Stivers JT: Potent inhibition of human apurinic/apyrimidinic endonuclease 1 by arylstibonic acids. Mol Pharmacol 73: 669-677, 2008.
54. Fishel ML and Kelley MR: The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target. Mol Aspects Med 28: 375-395, 2007.
55. Nathrath M, Kremer M, Letzel H, Remberger K, Höfler H and Ulle T: Expression of genes of potential importance in the response to chemotherapy in osteosarcoma patients. Klin Padiatr 214: 230-235, 2002 (In German).
56. Li X, Guo W, Shen DH, Yang RL, Liu J and Zhao H: Expressions of ERCC2 and ERCC4 genes in osteosarcoma and peripheral blood lymphocytes and their clinical significance. Beijing Da Xue Xue Bao 39: 467-471, 2007 (In Chinese).
57. Caronia D, Patiño-García A, Milne RL, Zalacain-Díez M, Pita G, Alonso MR, Moreno LT, et al: Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J 9: 347-353, 2009.
58. Biason P, Hattinger CM, Innocenti F, Talamini R, Alberghini M, Scotlandi K, Zanusso C, Serra M and Toffoli G: Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy. Pharmacogenomics J 12: 476-483, 2012.
59. Hao T, Feng W, Zhang J, Sun YJ and Wang G: Association of four ERCC1 and ERCC2 SNPs with survival of bone tumour patients. Asian Pac J Cancer Prev 13: 3821-3824, 2012.
60. Meric-Bernstam F and Gonzalez-Angulo AM: Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 27: 2278-2287, 2009.
61. Gordon IK, Ye F and Kent MS: Evaluation of the mammalian target of rapamycin pathway and the effect of rapamycin on target expression and cellular proliferation in osteosarcoma cells from dogs. Am J Vet Res 69: 1079-1084, 2008.
62. Gazitt Y, Kolapathi V, Moncada K, Thomas C and Freeman J: Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways. Int J Oncol 34: 551-561, 2009.
63. Zhou Q, Deng Z, Zhu Y, Long H, Zhang S and Zhao J: mTOR/p70S6K signal transduction pathway contributes to osteosarcoma progression and patients' prognosis. Med Oncol 27: 1239-1245, 2010.
64. Houghton PJ, Morton CL, Kolb EA, et al: Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 50: 799-805, 2008.
65. Wan X, Mendoza A, Khanna C and Helman LJ: Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 65: 2406-2411, 2005.
66. Mu X, Isaac C, Schott T, Huard J and Weiss K: Rapamycin inhibits ALDH activity, resistance to oxidative stress, and metastatic potential in murine osteosarcoma cells. Sarcoma 2013: 480713, 2013.
67. LeRoith D and Roberts CT Jr: The insulin-like growth factor system and cancer. Cancer Lett 195: 127-137, 2003.
68. Chitnis MM, Yuen JS, Protheroe AS, Pollak M and Macaulay VM: The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 14: 6364-6370, 2008.
69. Chou AJ, Merola PR, Sowers R, et al: Analysis of aberrant signal transduction pathways in osteosarcoma cell lines. Proc Amer Assoc Cancer Res 46: 4551, 2005.
70. Scotlandi K, Manara MC, Nicoletti G, et al: Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 65: 3868-3876, 2005.
71. Tanno B, Mancini C, Vitali R, et al: Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo. Clin Cancer Res 12: 6772-6780, 2006.
72. Hassan SE, Bekarev M, Kim MY, Lin J, Piperdi S, Gorlick R and Geller DS: Cell surface receptor expression patterns in osteosarcoma. Cancer 118: 740-749, 2012.
73. Luk F, Yu Y, Walsh WR and Yang JL: IGF1R-targeted therapy and its enhancement of doxorubicin chemosensitivity in human osteosarcoma cell lines. Cancer Invest 29: 521-532, 2011.
74. Wang YH, Xiong J, Wang SF, Yu Y, Wang B, Chen YX, Shi HF and Qiu Y: Lentivirus-mediated shRNA targeting insulin-like growth factor-1 receptor (IGF-1R) enhances chemosensitivity of osteosarcoma cells in vitro and in vivo. Mol Cell Biochem 341: 225-233, 2010.
75. Rettew AN, Young ED, Lev DC, Kleinerman ES, Abdul-Karim FW, Getty PJ and Greenfield EM: Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines. Oncogenesis 1: e34, 2012.
76. Wang YH, Han XD, Qiu Y, et al: Increased expression of insulin-like growth factor-1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma. J Surg Oncol 105: 235-243, 2012.
77. Gombos A, Metzger-Filho O, Dal Lago L and Awada-Hussein A: Clinical development of insulin-like growth factor receptor-1 (IGF-1R) inhibitors: at the crossroad? Invest New Drugs 30: 2433-2442, 2012.
78. Tap WD, Demetri GD, Barnette P, et al: AMG 479 in relapsed or refractory Ewing's family tumors (EFT) or desmoplastic small round cell tumors (DSRCT): Phase II results. J Clin Oncol 28: (15 Suppl), 10001, 2010.
79. Natinoal Institutes of Health: A Study to Determine the Activity of SCH 717454 in Subjects with Relapsed Osteosarcoma or Ewing's Sarcoma (Study P04720AM3). http://clinicaltrials.gov/ct2/show/NCT00617890?term=sch-717454&rank=2. Accessed April 6, 2011.
80. Akatsuka T, Wada T, Kokai Y, et al: ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 94: 1397-1404, 2002.
81. Zhou Q, Zhu Y, Deng Z, Long H, Zhang S and Chen X: VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma. Surg Oncol 20: 13-19, 2011.
82. Maris JM, Courtright J, Houghton PJ, et al: Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer 50: 581-587, 2008.
83. Ebb D, Meyers P, Grier H, et al: Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group. J Clin Oncol 30: 2545-2551, 2012.
84. Liebermann DA, Hoffman B and Steinman RA: Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. Oncogene 11: 199-210, 1995.
85. Asada N, Tsuchiya H and Tomita K: De novo deletions of p53 gene and wild-type p53 correlate with acquired cisplatin-resistance in human osteosarcoma OST cell line. Anticancer Res 19: 5131-5137, 1999.
86. Wong RP, Tsang WP, Chau PY, Co NN, Tsang TY and Kwok TT: p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3. Mol Cancer Ther 6: 1054-1061, 2007.
87. Fan J and Bertino JR: Modulation of cisplatinum cytotoxicity by p53: effect of p53-mediated apoptosis and DNA repair. Mol Pharmacol 56: 966-972, 1999.
88. Tsuchiya H, Mori Y, Ueda Y, Okada G and Tomita K: Sensitization and caffeine potentiation of cisplatin cytotoxicity resulting from introduction of wild-type p53 gene in human osteosarcoma. Anticancer Res 20: 235-242, 2000.
89. Sato N, Mizumoto K, Maehara N, Kusumoto M, Nishio S, Urashima T, Ogawa T and Tanaka M: Enhancement of drug-induced apoptosis by antisense oligodeoxynucleotides targeted against Mdm2 and p21WAF1/CIP1. Anticancer Res 20: 837-842, 2000.
90. Tang HJ, Qian D, Sondak VK, Stachura S and Lin J: A modified p53 enhances apoptosis in sarcoma cell lines mediated by doxorubicin. Br J Cancer 90: 1285-1292, 2004.
91. Goto A, Kanda H, Ishikawa Y, et al: Association of loss of heterozygosity at the p53 locus with chemoresistance in osteosarcomas. Jpn J Cancer Res 89: 539-547, 1998.
92. Pápai Z, Féja CN, Hanna EN, Sztán M, Oláh E and Szendrôi M: P53 overexpression as an indicator of overall survival and response to treatment in osteosarcomas. Pathol Oncol Res 3: 15-19, 1997.
93. Ozger H, Eralp L, Atalar AC, et al: The effect of resistance-related proteins on the prognosis and survival of patients with osteosarcoma: an immunohistochemical analysis. Acta Orthop Traumatol Turc 43: 28-34, 2009 (In Turkish).
94. Wunder JS, Gokgoz N, Parkes R, et al: TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol 23: 1483-1490, 2005.
95. Chao DT and Korsmeyer SJ: BCL-2 family: regulators of cell death. Ann Rev Immunol 16: 395-419, 1998.
96. Reed JC: Double identity for proteins of the Bcl-2 family. Nature 387: 773-776, 1997.
97. Korsmeyer SJ: BCL-2 gene family and the regulation of programmed cell death. Cancer Res 59 (7 Suppl): 1693s-1700s, 1999.
98. Ye D, Li H, Qian S, Sun Y, Zheng J and Ma Y: bcl-2/bax expression and p53 gene status in human bladder cancer: relationship to early recurrence with intravesical chemotherapy after resection. J Urol 160: 2025-2029, 1998.
99. Han JY, Chung YJ, Park SW, Kim JS, Rhyu MG, Kim HK and Lee KS: The relationship between cisplatin-induced apoptosis and p53, bcl-2 and bax expression in human lung cancer cells. Korean J Intern Med 14: 42-52, 1999.
100. Luo D, Cheng SC, Xie H and Xie Y: Chemosensitivity of human hepatocellular carcinoma cell line QGY-7703 is related to bcl-2 protein levels. Tumour Biol 20: 331-340, 1999.
101. Murata T, Haisa M, Uetsuka H, et al: Molecular mechanism of chemoresistance to cisplatin in ovarian cancer cell lines. Int J Mol Med 13: 865-868, 2004.
102. Perego P, Righetti SC, Supino R, et al: Role of apoptosis and apoptosis-related proteins in the cisplatin-resistant phenotype of human tumor cell lines. Apoptosis 2: 540-548, 1997.
103. Zhao Y, Zhang CL, Zeng BF, Wu XS, Gao TT and Oda Y: Enhanced chemosensitivity of drug-resistant osteosarcoma cells by lentivirus-mediated Bcl-2 silencing. Biochem Biophys Res Commun 390: 642-647, 2009.
104. Zhang C, Zhao Y and Zeng B: Enhanced chemosensitivity by simultaneously inhibiting cell cycle progression and promoting apoptosis of drug-resistant osteosarcoma MG63/DXR cells by targeting Cyclin D1 and Bcl-2. Cancer Biomark 12: 155-167, 2012.
105. Dey R and Moraes CT: Lack of oxidative phosphorylation and low mitochondrial membrane potential decrease susceptibility to apoptosis and do not modulate the protective effect of Bcl-x(L) in osteosarcoma cells. J Biol Chem 275: 7087-7094, 2000.
106. Zangemeister-Wittke U: Antisense to apoptosis inhibitors facilitates chemotherapy and TRAIL-induced death signaling. Ann NY Acad Sci 1002: 90-94, 2003.
107. Zhang L, Yu J, Park BH, et al: Role of BAX in the apoptotic response to anticancer agents. Science 290: 989-992, 2000.
108. Eliseev RA, Dong YF Sampson E, et al: Runx2-mediated activation of the Bax gene increases osteosarcoma cell sensitivity to apoptosis. Oncogene 27: 3605-3614, 2008.
109. Cao X, Bennett RL and May WS: c-Myc and caspase-2 are involved in activating Bax during cytotoxic drug-induced apoptosis. J Biol Chem 283: 14490-14496, 2008.
110. Ferrari S, Bertoni F, Zanella L, et al: Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma. Cancer 100: 1936-1942, 2004.
111. Wu X, Cai ZD, Lou LM and Zhu YB: Expressions of p53, c-MYC, BCL-2 and apoptotic index in human osteosarcoma and their correlations with prognosis of patients. Cancer Epidemiol 36: 212-216, 2012.
112. Wang ZX, Yang JS, Pan X, Wang JR, Li J, Yin YM and De W: Functional and biological analysis of Bcl-xL expression in human osteosarcoma. Bone 47: 445-454, 2010.
113. Nedelcu T, Kubista B, Koller A, et al: Livin and Bcl-2 expression in high-grade osteosarcoma. J Cancer Res Clin Oncol 134: 237-244, 2008.
114. Kaseta MK, Khaldi L, Gomatos IP, et al: Prognostic value of bax, bcl-2, and p53 staining in primary osteosarcoma. J Surg Oncol 97: 259-266, 2008.
115. Kaseta MK, Gomatos IP, Khaldi L, et al: Prognostic value of bax, cytochrome C, and caspase-8 protein expression in primary osteosarcoma. Hybridoma (Larchmt) 26: 355-362, 2007.
116. Degenhardt K, Mathew R, Beaudoin B, et al: Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 10: 51-64, 2006.
117. Klionsky DJ and Emr SD: Autophagy as a regulated pathway of cellular degradation. Science 290: 1717-1721, 2000.
118. Maiuri MC, Zalckvar E, Kimchi A and Kroemer G: Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 8: 741-752, 2007.
119. Kroemer G and Levine B: Autophagic cell death: the story of a misnomer. Nat Rev Mol Cell Biol 9: 1004-1010, 2008.
120. Han J, Hou W, Goldstein LA, et al: Involvement of protective autophagy in TRAIL resistance of apoptosis-defective tumor cells. J Biol Chem 283: 19665-19677, 2008.
121. Amaravadi RK, Yu D, Lum JJ, et al: Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 117: 326-336, 2007.
122. Carew JS, Medina EC, Esquivel JA II, et al: Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. J Cell Mol Med 14: 2448-2459, 2010.
123. Wu Z, Chang PC, Yang JC, et al: Autophagy blockade sensitizes prostate cancer cells towards Src family kinase inhibitors. Genes Cancer 1: 40-49, 2010.
124. Li J, Hou N, Faried A, Tsutsumi S and Kuwano H: Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model. Eur J Cancer 46: 1900-1909, 2010.
125. White E and DiPaola RS: The double-edged sword of autophagy modulation in cancer. Clin Cancer Res 15: 5308-5316, 2009.
126. Katayama M, Kawaguchi T, Berger MS and Pieper RO: DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death Differ 14: 548-558, 2007.
127. Carew JS, Nawrocki ST, Kahue CN, et al: Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 110: 313-322, 2007.
128. Lambert LA, Qiao N, Hunt KK, Lambert DH, Mills GB, Meijer L and Keyomarsi K: Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Res 68: 7966-7974, 2008.
129. Meschini S, Condello M, Calcabrini A, et al: The plant alkaloid voacamine induces apoptosis-independent autophagic cell death on both sensitive and multidrug resistant human osteosarcoma cells. Autophagy 4: 1020-1033, 2008.
130. Kim HJ, Lee SG, Kim YJ, Park JE, Lee KY, Yoo YH and Kim JM: Cytoprotective role of autophagy during paclitaxel-induced apoptosis in Saos-2 osteosarcoma cells. Int J Oncol 42: 1985-1992, 2013.
131. Zhang Z, Shao Z, Xiong L, Che B, Deng C and Xu W: Expression of Beclin1 in osteosarcoma and the effects of down-regulation of autophagy on the chemotherapeutic sensitivity. J Huazhong Univ Sci Technolog Med Sci 29: 737-740, 2009.
132. Coupienne I, Fettweis G and Piette J: RIP3 expression induces a death profile change in U2OS osteosarcoma cells after 5-ALA-PDT. Lasers Surg Med 43: 557-564, 2011.
133. Huang J, Ni J, Liu K, et al: HMGB1 promotes drug resistance in osteosarcoma. Cancer Res 72: 230-238, 2012.
134. Huang J, Liu K, Yu Y, et al: Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma. Autophagy 8: 275-277, 2012.
135. Pillai RS, Bhattacharyya SN and Fillipowicz W: Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol 17: 118-126, 2007.
136. Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature 435: 834-838, 2005.
137. Volinia S, Calin GA, Liu CG, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261, 2006.
138. Nakatani F, Ferracin M, Manara MC, et al: miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy. J Pathol 226: 796-805, 2012.
139. Gougelet A, Pissaloux D, Besse A, et al: Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. Int J Cancer 129: 680-690, 2011.
140. Song B, Wang Y, Xi Y, et al: Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 28: 4065-4074, 2009.
141. Song B, Wang Y, Titmus MA, Botchkina G, Formentini A, Kornmann M and Ju J: Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol Cancer 9: 96, 2010.
142. Cai CK, Zhao GY, Tian LY, et al: miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma. Oncol Rep 28: 1764-1770, 2012.
143. Makino S: The role of tumor stem-cells in regrowth of the tumor following drastic applications. Acta Unio Int Contra Cancrum 15 (Suppl 1): 196-198, 1959.
144. Bonnet D and Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737, 1997.
145. Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD and Steindler DA: Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 39: 193-206, 2002.
146. Singh SK, Clarke ID, Terasaki M, et al: Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828, 2003.
147. Liu B, Ma W, Jha RK and Gurung K: Cancer stem cells in osteosarcoma: recent progress and perspective. Acta Oncol 50: 1142-1150, 2011.
148. Woodward WA and Sulman EP: Cancer stem cells: markers or biomarkers? Cancer Metastasis Rev 27: 459-470, 2008.
149. Vangipuram SD, Wang ZJ and Lyman WD: Resistance of stem-like cells from neuroblastoma cell lines to commonly used chemotherapeutic agents. Pediatr Blood Cancer 54: 361-368, 2010.
150. Di Fiore R, Santulli A, Ferrante RD, et al: Identification and expansion of human osteosarcoma-cancer-stem cells by long-term 3-aminobenzamide treatment. J Cell Physiol 219: 301-313, 2009.
151. Fujii H, Honoki K, Tsujiuchi T, Kido A, Yoshitani K and Takakura Y: Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines. Int J Oncol 34: 1381-1386, 2009.
152. Honoki K, Fujii H, Kubo A, Kido A, Mori T, Tanaka Y and Tsujiuchi T: Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance. Oncol Rep 24: 501-505, 2010.
153. Martins-Neves SR, Lopes ÁO, do Carmo A, et al: Therapeutic implications of an enriched cancer stem-like cell population in a human osteosarcoma cell line. BMC Cancer 12: 139, 2012.
154. Chou AJ, Merola PR, Wexler LH, et al: Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience. Cancer 104: 2214-2221, 2005.
155. Alberts DS, Muggia FM, Carmichael J, et al: Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol 31 (Suppl 13): S53-S90, 2004.
156. Maes H, Rubio N, Garg AD and Agostinis P: Autophagy: shaping the tumor microenvironment and therapeutic response. Trends Mol Med 19: 428-446, 2013.